annual meeting program - American Society of Clinical Oncology

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION
Breast Cancer—Metastatic
Display Time: 8:00 AM - 12:00 PM
Display Location: E450b
Discussion Time: 12:00 PM - 1:00 PM
Discussion Location: E Hall D1
CME credit: 1
Track(s): Breast Cancer
Saturday, June 5, 2010
Anne F. Schott, MD—Co-Chair
University of Michigan
Hope S. Rugo, MD—Co-Chair
University of California, San Francisco
Discussion
12:00 PM David A. Cameron, MD (Abstracts #1012–1016)
Edinburgh University
Discussion
12:15 PM Lisa A. Carey, MD (Abstracts #1017–1021, 1031)
University of North Carolina at Chapel Hill
Discussion
12:30 PM Catherine H. Van Poznak, MD (Abstracts #1022–1026)
University of Michigan
Discussion
12:45 PM Nancy U. Lin, MD (Abstracts #1027–1030)
Dana-Farber Cancer Institute
Brd. 1 A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for
women with HER2-positive, locally advanced or metastatic breast cancer
(BC) who were previously treated with trastuzumab (T). (Abstract #1012)
K. Miller, L. Gianni, F. Andre, V. Dieras, R. L. Mahtani, N. Harbeck, J. E. Huang,
T. Shih, Y. Choi, H. A. Burris III
Brd. 2 Everolimus in combination with weekly paclitaxel and trastuzumab in
patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with
prior resistance to trastuzumab and taxanes: A multicenter phase II clinical
trial. (Abstract #1013^)
F. Dalenc, M. Campone, P. Hupperets, R. O’Regan, C. Manlius, L. Vittori,
P. Mukhopadhyay, C. Massacesi, T. Sahmoud, F. Andre
Brd. 3 Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with
trastuzumab-resistant, HER2-overexpressing breast cancer. (Abstract #1014)
P. H. Morrow, G. M. Wulf, D. J. Booser, J. A. Moore, P. R. Flores, I. E. Krop,
E. P. Winer, G. N. Hortobagyi, D. Yu, F. J. Esteva
Brd. 4 Correlation of cyclin D1, A870G, polymorphism, and clinical outcome in
patients with HER2-positive, metastatic breast cancer treated with lapatinib
plus capecitabine. (Abstract #1015)
M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, R. D. Ladner, T. Winder,
P. O. Bohanes, Y. Ning, H. Lenz
Brd. 5 Quantitative assessment of diagnostic markers and correlations with
efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts)
with metastatic breast cancer (MBC) who had progressed on prior HER2directed
therapy. (Abstract #1016)
P. LoRusso, I. E. Krop, H. A. Burris III, S. J. Vukelja, K. Miller, M. Zheng, Y. Chu,
M. Lu, L. C. Amler, H. S. Rugo
115
SATURDAY